Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT et al.
Pharmacological Reviews, 2016
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C et al.
Drug Metabolism and Pharmacokinetics, 2015
Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Daily EB et al.
Pharmacogenomics, 2009
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
Saito Y et al.
Pharmacogenetics and Genomics, 2007
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Nakajima Y et al.
Clinical Pharmacology and Therapeutics, 2006
Select a paper to view details